• Pre Clinical And Clinical Research

ValiRx signals launch of new strategy with Nottingham laboratories

ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has taken the lease on laboratory and office facilities at MediCity Nottingham as it embarks on the next stage of its strategy to launch a translational Contract Research Organisation (tCRO).

Arecor announces publication of Phase I data for AT278 in diabetes care

Ultra-concentrated, ultra-rapid acting insulin AT278, a promising candidate in the pursuit of next generation insulins to simplify and improve glycemic control

Real-world evidence: the panacea for rare diseases?

The publication of the National Institute for Health and Care Excellence’s real-world evidence framework in June 2022 has accelerated discussions about the role that real-world evidence can play in resolving gaps in knowledge and driving forward access to innovations for patients with rare diseases. Senior Policy and Public Affairs Executive, Joe Smale, reflects on a recent BIA-facilitated discussion on the potential of real-world evidence in rare diseases and the importance of patient involvement in future discussions.

Ingenza collaborates with Amplifica to advance novel alopecia treatments

Industrial biotech specialist Ingenza recently announce it is collaborating with clinical-stage biopharmaceutical company Amplifica Holdings Group, Inc. to develop an innovative treatment to address androgenic alopecia.

Industry-first cancer screening technology boosted by biomedical grant funding

Medicines Discovery Catapult and SMi secure funding to validate cancer biomarker technology

CEO Update | 9 January 2023

I write this week from San Francisco where the JPM conference is now well underway – with full participation from the UK ecosystem. Folk are already talking about  the announcement of BioNtech’s MoU with the UK Government to develop next generation cancer vaccines in partnership. Also demonstrating the UK’s capability in accelerated innovation is the news from RQ Bio and AstraZeneca that the first of RQ’s monoclonal antibodies to prevent COVID-19 in vulnerable patients, which originates from work of the BIA Antibody Taskforce, has entered clinical trials less than 12 months after discovery, with the start of AZ’s SUPERNOVA Phase I/III trial.

Evaluating Inhaled Aerosol Vaccines: No-needle COVID-19 Protection?

The COVID-19 epidemic has now entered its third year with its effects still being felt across the world. In many countries, there have been an alarming trend of waning vaccine efficacy paired with the emergence of variants with stronger immune escape and transmission ability. This consistent challenging of our pre-established immune barriers has driven the need for new, innovative vaccine modalities that overcome the hurdles of existing vaccination programs.

Alchemab Therapeutics and MDC awarded £1.7m grant to accelerate development of disease-modifying therapy for Huntington’s Disease

Alchemab Therapeutics, a biotechnology company unlocking new therapies from within the immune system, today announced that it has been awarded a grant of £1.7 million (US$2 million) from Innovate UK’s Biomedical Catalyst (‘BMC’) 2022 funding competition, to accelerate development of a first-in-class disease-modifying therapy for Huntington’s disease. Working in collaboration with Medicines Discovery Catapult (‘MDC’), Alchemab is carrying out preclinical studies to progress its panel of antibodies towards first-in-human studies.

ValiRx appoints preclinical project manager to drive development of triple breast cancer treatment

ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has appointed a project manager to lead the preclinical development of its in-licensed triple negative breast cancer treatment, CLX001.

New targeted drug shows benefit against breast cancer in first phase III trial

Capivasertib alongside hormone therapy doubles time before advanced breast cancer progresses; combination set to become new treatment option for patients with advanced forms of most common type of breast cancer; inhibitor of cancer-driving protein AKT shows broad benefits in patients with ER positive, HER2 negative breast cancer.